AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24884422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate 2.5%
Number of subjects: 411
Study 24884422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate 1%
Number of subjects: 411
Study 24884422 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone acetate 0.5%
Number of subjects: 411
Study 23275415 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oppositions approach (3 times per week for 8 weeks)
Number of subjects: 54
Study 23275415 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oppositions approach (once weekly for 24 weeks)
Number of subjects: 54
Study 23275415 — intervention group
Group type: COMPARATOR
Intervention: Control condition (storybook intervention)
Number of subjects: 54
Study 20708511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic filing (with PL)
Number of subjects: 32
Study 20708511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic filing (without PL)
Number of subjects: 32
Study 20708511 — intervention group
Group type: COMPARATOR
Intervention: Hand filing (with PL)
Number of subjects: 32
Study 20708511 — intervention group
Group type: COMPARATOR
Intervention: Hand filing (without PL)
Number of subjects: 32
Study 18469735 — intervention group
Group type: EXPERIMENTAL
Intervention: Playstation EyeToy Games
Number of subjects: 20
Study 15672427 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 53
Study 15672427 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 53
Study 14698649 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin injection (2 ng/kg)
Number of subjects: 9
Study 10554799 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (5 mg/kg/d)
Number of subjects: 581
Study 10554799 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (100 mg)
Number of subjects: 581
Study 8665036 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled heparin (1,000 U/kg/dose)
Number of subjects: 8
Study 8665036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2059298 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (low-dose cyclosporin A, low-dose methylprednisolone, azathioprine)
Number of subjects: 128
Study 2059298 — intervention group
Group type: COMPARATOR
Intervention: Aza and CyA (double drug treatment)
Number of subjects: 128
Study 2059298 — intervention group
Group type: COMPARATOR
Intervention: Aza and MP (double drug treatment)
Number of subjects: 128
Study 2059298 — intervention group
Group type: COMPARATOR
Intervention: CyA and MP (double drug treatment)
Number of subjects: 128
Study 3841079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily)
Number of subjects: 104
Study 3841079 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 104
Study 30066148 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 30066148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 27523921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 μg)
Number of subjects: 390
Study 27523921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 μg)
Number of subjects: 390
Study 27523921 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 390
Study 27523921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 390
Study 27523921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 390
Study 27523921 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 390
Study 24140166 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (100 mg)
Number of subjects: 12
Study 24140166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 22378657 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg daily at bedtime)
Number of subjects: 10
Study 22378657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20733210 — intervention group
Group type: EXPERIMENTAL
Intervention: External visual imagery with high self-enhancement
Number of subjects: 0
Study 20733210 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal visual imagery with high self-enhancement
Number of subjects: 0
Study 20733210 — intervention group
Group type: EXPERIMENTAL
Intervention: Low narcissists across self-enhancement conditions
Number of subjects: 0
Study 18561728 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (1 x 10 mg/kg, then 2 x 5 mg/kg at 24‐hour intervals)
Number of subjects: 20
Study 18561728 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin (3 x 0.2 mg/kg at 24‐hour intervals)
Number of subjects: 20
Study 17605699 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Quality Use of Medicines program (academic detailing, prescribing information, feedback, medication risk assessment, medication review facilitation, financial incentives)
Number of subjects: 849
Study 17605699 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Quality Use of Medicines program
Number of subjects: 849
Study 15564950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (3 mg)
Number of subjects: 20
Study 15564950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11111068 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg per hour sustained-release polymer vaginal prostaglandin E(2) insert
Number of subjects: 24
Study 9486510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg IV post-partum, followed by 10 mg at 12 h and 10 mg at 24 h, total 30 mg)
Number of subjects: 34
Study 9486510 — intervention group
Group type: COMPARATOR
Intervention: Control (no corticosteroids)
Number of subjects: 34
Study 8397516 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (50% of energy)
Number of subjects: 6
Study 8397516 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy)
Number of subjects: 6
Study 8397516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber content (2 or 4 g/MJ)
Number of subjects: 6
Study 8397516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic variables (t‐PA and PAI‐1 antigen, PAI activity, t‐PA and euglobulin fibrinolytic activity)
Number of subjects: 6
Study 3486546 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg, 2 ml) injected i.v. after arm exercise
Number of subjects: 11
Study 3486546 — intervention group
Group type: COMPARATOR
Intervention: Saline (2 ml) injected i.v. after arm exercise
Number of subjects: 11
Study 3486546 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle exercise (20 min)
Number of subjects: 11
Study 3486546 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency TNS (30 min)
Number of subjects: 11
Study 3486546 — intervention group
Group type: EXPERIMENTAL
Intervention: Face stimulation (low frequency TNS)
Number of subjects: 11
Study 29900538 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight (HMW) adiponectin
Number of subjects: 0
Study 29900538 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW adiponectin <1.53 μg/mL
Number of subjects: 0
Study 29900538 — intervention group
Group type: COMPARATOR
Intervention: Fasting glucose (FG) and maternal factors
Number of subjects: 0
Study 29900538 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW adiponectin
Number of subjects: 0
Study 29900538 — intervention group
Group type: COMPARATOR
Intervention: FG and maternal factors
Number of subjects: 0
Study 29900538 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentin-1 and IL-6
Number of subjects: 0
Study 29415841 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST)
Number of subjects: 110
Study 29415841 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST) recommendations for viscosity
Number of subjects: 110
Study 29415841 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST) recommendations for volume
Number of subjects: 110
Study 29415841 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST) overall prevalence of OD
Number of subjects: 110
Study 29415841 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST) PABAK
Number of subjects: 110
Study 29415841 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST) mean time to perform the test
Number of subjects: 110
Study 26197846 — intervention group
Group type: EXPERIMENTAL
Intervention: rmPCR
Number of subjects: 617
Study 26197846 — intervention group
Group type: EXPERIMENTAL
Intervention: rmPCR/AS
Number of subjects: 617
Study 26197846 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 617
Study 22231540 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (hot spring immersion at 40°C for 10 min daily for 2 weeks)
Number of subjects: 32
Study 22231540 — intervention group
Group type: COMPARATOR
Intervention: Control (daily shower)
Number of subjects: 32
Study 22231540 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (hot spring immersion)
Number of subjects: 32
Study 21921573 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy under combined spinal-epidural anesthesia (CSEA)
Number of subjects: 64
Study 21921573 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy under general anesthesia (GA)
Number of subjects: 64
Study 19633594 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed safe intravenous system (COSMOS - Compact Closed System)
Number of subjects: 0
Study 19633594 — intervention group
Group type: COMPARATOR
Intervention: Open system (Mounted Open System)
Number of subjects: 0
Study 15967695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal histamine (8 mg/ml, 0.1 ml)
Number of subjects: 20
Study 15967695 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline challenge
Number of subjects: 20
Study 15967695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal histamine followed by intensified nasal and mouth breathing
Number of subjects: 20
Study 14689348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (400 mg daily for 3 days, then 400 mg every 4 weeks for 5 months)
Number of subjects: 104
Study 11054066 — intervention group
Group type: EXPERIMENTAL
Intervention: Interphase fluorescence in situ hybridization (IFISH)
Number of subjects: 64
Study 11054066 — intervention group
Group type: COMPARATOR
Intervention: Conventional marrow cytogenetic karyotype
Number of subjects: 64
Study 9323645 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue-based protocol using surface EMG during isometric contraction at 80% of maximal voluntary contraction (MVC) force
Number of subjects: 0
Study 9323645 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of new test procedures for EMG parameters
Number of subjects: 0
Study 9323645 — intervention group
Group type: EXPERIMENTAL
Intervention: Model to predict MVC from anthropometrical measurements
Number of subjects: 0
Study 7679885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy (Hot/Ice Thermal Blanket) applied to 13 patients
Number of subjects: 27
Study 7679885 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 27
Study 3763140 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified grid argon (blue-green) laser photocoagulation
Number of subjects: 92
Study 3763140 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 92
Study 31182217 — intervention group
Group type: EXPERIMENTAL
Intervention: FamLit intervention (multi-component, family-focused, literacy-sensitive)
Number of subjects: 43
Study 31182217 — intervention group
Group type: COMPARATOR
Intervention: Attention-only intervention (control group)
Number of subjects: 43
Study 29037884 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage group (A)
Number of subjects: 108
Study 29037884 — intervention group
Group type: COMPARATOR
Intervention: Non-drainage group (B)
Number of subjects: 108
Study 27466222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft (Auto group)
Number of subjects: 107
Study 27466222 — intervention group
Group type: COMPARATOR
Intervention: Irradiated hamstring tendon allograft (Ir-Allo group)
Number of subjects: 107
Study 24401802 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) with ropivacaine 0.75%, 30 ml at time 0 and isotonic saline after 45 min
Number of subjects: 50
Study 24401802 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block (ACB) with isotonic saline at time 0 and ropivacaine 0.75%, 30 ml after 45 min
Number of subjects: 50
Study 22743177 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine supplementation
Number of subjects: 76
Study 22743177 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cytokine levels
Number of subjects: 76
Study 22743177 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cytokine levels
Number of subjects: 76
Study 20610587 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (leuprolide acetate, 7.5 mg im every 28 d)
Number of subjects: 41
Study 20610587 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections (control)
Number of subjects: 41
Study 18044260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg) plus voglibose
Number of subjects: 31
Study 18044260 — intervention group
Group type: COMPARATOR
Intervention: Voglibose alone
Number of subjects: 31
Study 16583834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime prophylaxis
Number of subjects: 1000
Study 16583834 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 1000
Study 11478566 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component parenting intervention
Number of subjects: 286
Study 11478566 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies (incentives, tracking, culturally competent staff)
Number of subjects: 286
Study 9621668 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with low dose fentanyl (8 micrograms.kg‐1)
Number of subjects: 40
Study 9621668 — intervention group
Group type: COMPARATOR
Intervention: High dose fentanyl anesthesia (100 micrograms.kg‐1)
Number of subjects: 40
Study 7871354 — intervention group
Group type: EXPERIMENTAL
Intervention: Suscard (lactose-containing nitroglycerin tablet)
Number of subjects: 12
Study 7871354 — intervention group
Group type: COMPARATOR
Intervention: Sucrose-containing lozenge (control)
Number of subjects: 12
Study 7871354 — intervention group
Group type: COMPARATOR
Intervention: Normal oral hygiene procedures
Number of subjects: 12
Study 3268159 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative four-vessel angiography
Number of subjects: 148
Study 3268159 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate limited angiography
Number of subjects: 148
Study 3268159 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial CT scanning (abnormal)
Number of subjects: 148
Study 3268159 — intervention group
Group type: EXPERIMENTAL
Intervention: CT abnormalities
Number of subjects: 148
Study 3268159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 148
Study 29996082 — intervention group
Group type: EXPERIMENTAL
Intervention: H4:IC31 vaccine
Number of subjects: 990
Study 29996082 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 990
Study 29996082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990
Study 25967068 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated pants
Number of subjects: 82
Study 25967068 — intervention group
Group type: COMPARATOR
Intervention: Non-treated pants (control group)
Number of subjects: 82
Study 25447444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion 2 mg/kg/h after bolus 1.5 mg/kg
Number of subjects: 153
Study 25447444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined infusion of lidocaine and dexmedetomidine
Number of subjects: 153
Study 25447444 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 153
Study 21951549 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide SC, 500 μg three times daily for 7 days
Number of subjects: 15
Study 21951549 — intervention group
Group type: COMPARATOR
Intervention: Placebo SC for 7 days
Number of subjects: 15
Study 21951549 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label octreotide LAR 30 mg offered to all responders on day 14
Number of subjects: 15
Study 20224901 — intervention group
Group type: EXPERIMENTAL
Intervention: SEIQoL-DW intervention administered 3-5 times per patient
Number of subjects: 13
Study 20224901 — intervention group
Group type: EXPERIMENTAL
Intervention: SEIQoL-DW intervention
Number of subjects: 13
Study 17905013 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy plus large-balloon dilation (12- to 20-mm balloon diameter)
Number of subjects: 200
Study 17905013 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy alone
Number of subjects: 200
Study 16037891 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 36
Study 12160281 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapedectomy revision in elderly patients
Number of subjects: 120
Study 12160281 — intervention group
Group type: COMPARATOR
Intervention: Stapedectomy revision in younger patients (control group)
Number of subjects: 120
Study 10660149 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐alpha2a
Number of subjects: 21
Study 10660149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8638799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 6
Study 8638799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1325831 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg o.d.
Number of subjects: 21
Study 1325831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg o.d.
Number of subjects: 21
Study 6441542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (300 mg/day) and low dose aspirin (150 mg/day) until delivery
Number of subjects: 100
Study 6441542 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 100
Study 29356827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention (diet, exercise, cognitive training, and vascular risk management)
Number of subjects: 1109
Study 29356827 — intervention group
Group type: COMPARATOR
Intervention: General health advice (Control)
Number of subjects: 1109
Study 26428409 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin, 60 μg/kg, intravenously as a single dose 3 days before and 0, +1, and +2 post autologous HSCT infusion
Number of subjects: 0
Study 25056465 — intervention group
Group type: EXPERIMENTAL
Intervention: 60° mediolateral episiotomy
Number of subjects: 330
Study 25056465 — intervention group
Group type: COMPARATOR
Intervention: 40° mediolateral episiotomy
Number of subjects: 330
Study 22382148 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+)CD38(+)HLADR(+)%, CD4(+)CD38(‐)HLADR(+)%, CD8(+)CD38(+)HLADR(+)%; measured in relation to full-scale Intelligence Quotient scores (FSIQ)
Number of subjects: 126
Study 22382148 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+)CD38(+)HLADR(‐)%
Number of subjects: 126
Study 19462314 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan-HCT combination therapy (candesartan 2-32 mg and HCT 6.25-25 mg)
Number of subjects: 4632
Study 19462314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4632
Study 17459238 — intervention group
Group type: EXPERIMENTAL
Intervention: 1CU accommodative intraocular lens
Number of subjects: 54
Study 17459238 — intervention group
Group type: COMPARATOR
Intervention: Array multifocal intraocular lens
Number of subjects: 54
Study 15919302 — intervention group
Group type: EXPERIMENTAL
Intervention: SaphLITE vein harvest (SVH)
Number of subjects: 225
Study 15919302 — intervention group
Group type: COMPARATOR
Intervention: Conventional open vein harvest (OVH)
Number of subjects: 225
Study 11226654 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique for burn depth measurement based on histological assessment of dermal microvascular occlusion
Number of subjects: 5
Study 11226654 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique for burn depth measurement
Number of subjects: 5
Study 10072988 — intervention group
Group type: EXPERIMENTAL
Intervention: qi-gong therapy (group b: 12 GYSK cases, group c: 19 YXYK cases)
Number of subjects: 45
Study 10072988 — intervention group
Group type: COMPARATOR
Intervention: nifedipine therapy (group d)
Number of subjects: 45
Study 8420857 — intervention group
Group type: EXPERIMENTAL
Intervention: Iced injectate
Number of subjects: 21
Study 8420857 — intervention group
Group type: COMPARATOR
Intervention: Room temperature injectate
Number of subjects: 21
Study 3773799 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E therapy (300 mg/day intramuscularly for seven days)
Number of subjects: 41
Study 3773799 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 41
Study 2656333 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide‐5‐mononitrate, orally, three times daily for 4 weeks
Number of subjects: 126
Study 2656333 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine, orally, three times daily for 4 weeks
Number of subjects: 126
Study 2656333 — intervention group
Group type: COMPARATOR
Intervention: 20 mg isosorbide‐5‐mononitrate
Number of subjects: 126
Study 2656333 — intervention group
Group type: COMPARATOR
Intervention: 20 mg nifedipine
Number of subjects: 126
Study 2656333 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 126
Study 31288831 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide 5 mg daily oral intake for 21 days
Number of subjects: 80
Study 31288831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31288831 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 80
Study 28339460 — intervention group
Group type: EXPERIMENTAL
Intervention: IPB only
Number of subjects: 1112
Study 28339460 — intervention group
Group type: EXPERIMENTAL
Intervention: IPB+
Number of subjects: 1112